Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)



Status:Recruiting
Conditions:Atrial Fibrillation
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:September 4, 2018
End Date:September 30, 2020

Use our guide to learn which trials are right for you!

Evaluation of the VISITAG SURPOINT™ Module With External Processing Unit (EPU) When Used With the THERMOCOOL SMARTTOUCH® SF and the THERMOCOOL SMARTTOUCH® Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA)

Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module
with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to
an historical control performance goal.

A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280)
enrolled subjects will be treated using the STSF catheter with EPU and 50 subjects will be
treated using the ST catheter with EPU. Prior to enrollment, a few sites will be selected to
only enroll subjects who will be treated with the ST catheter and the remaining sites will
only enroll subjects who will be treated with the STSF catheter.

Bayesian adaptive design will be used to assess early success at up to two interims: one
after all subjects have completed the 3- month follow-up assessment, and a second to occur
after all subjects have completed the 6 months follow-up visit.

Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module
with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to
an historical control performance goal.

A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280)
enrolled subjects will be treated using the STSF catheter with EPU and 50 subjects will be
treated using the ST catheter with EPU. Prior to enrollment, a few sites will be selected to
only enroll subjects who will be treated with the ST catheter and the remaining sites will
only enroll subjects who will be treated with the STSF catheter.

Bayesian adaptive design will be used to assess early success at up to two interims: one
after all subjects have completed the 3- month follow-up assessment, and a second to occur
after all subjects have completed the 6 months follow-up visit.

The primary objective of this clinical investigation is to demonstrate the safety and
12-month effectiveness of Tag Index-guided ablation using the VISITAG SURPOINT™ Module with
External Processing Unit when used with the THERMOCOOL SMARTTOUCH® SF (STSF) and THERMOCOOL
SMARTTOUCH® (ST) catheters for pulmonary vein isolation (PVI) in the treatment of subjects
with drug refractory symptomatic paroxysmal atrial fibrillation. Specifically:

- To demonstrate the safety based on the proportion of subjects with early-onset (within 7
days of ablation procedure) primary adverse events

- To demonstrate the 12-month effectiveness based on the proportion of subject with
freedom from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia
(AT) or atrial flutter (AFL) episodes during the effectiveness evaluation period (Day
91-365)

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation
in this study:

1. Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically
documented within one (1) year prior to enrollment. Documentation may include
electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry
strip

2. Failed at least one antiarrhythmic drug (AAD) (Class I or III antiarrhythmic drugs) as
evidenced by recurrent symptomatic AF, or intolerable to the AAD

3. Age 18 years or older

4. Signed Patient Informed Consent Form (ICF)

5. Able and willing to comply with all pre-, post-, and follow-up testing and
requirements

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not eligible for enrollment.

1. Previous surgical or catheter ablation for atrial fibrillation

2. Previous cardiac surgery (including CABG) within the past 6 months (180 days)

3. Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and
valve repair or replacement and presence of a prosthetic valve)

4. Any carotid stenting or endarterectomy

5. Documented LA thrombus on imaging

6. LA size > 50 mm (parasternal long axis view)

7. LVEF < 40%

8. Contraindication to anticoagulation (heparin or warfarin)

9. History of blood clotting or bleeding abnormalities

10. PCI/MI within the past 2 months (60 days)

11. Documented thromboembolic event (including TIA) within the past 12 months (365 days)

12. Rheumatic Heart Disease

13. Uncontrolled heart failure or NYHA function class III or IV

14. Severe mitral regurgitation (Regurgitant volume ≥ 60 mL/beat, Regurgitant fraction ≥
50%, and/or Effective regurgitant orifice area ≥ 0.40cm2)

15. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months
(365 days)

16. Unstable angina

17. Acute illness or active systemic infection or sepsis

18. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
cause.

19. Presence of implanted ICD/CRT-D.

20. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or
chronic obstructive pulmonary disease) or any other disease or malfunction of the
lungs or respiratory system that produces chronic symptoms.

21. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not
including OTC medication)

22. Significant congenital anomaly or medical problem that in the opinion of the
investigator would preclude enrollment in this study.

23. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)

24. Concurrent enrollment in an investigational study evaluating another device, biologic,
or drug.

25. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other
abnormality that precludes vascular access, or manipulation of the catheter.

26. Life expectancy less than 12 months
We found this trial at
15
sites
Austin, Texas 78705
Phone: 512-458-9410
?
mi
from
Austin, TX
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Phone: 205-934-2525
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Albany, New York 12208
Phone: 518-262-2324
?
mi
from
Albany, NY
Click here to add this to my saved trials
811 Wright Street
Arlington, Texas 76012
Phone: 682-223-9120
?
mi
from
Arlington, TX
Click here to add this to my saved trials
Atlanta, Georgia 30342
Phone: 404-778-6070
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Birmingham, Alabama 35243
Phone: 205-971-7578
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Columbus, Ohio 43210
Phone: 614-293-4967
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Kensington, Kentucky 40503
Phone: 859-260-6368
?
mi
from
Kensington, KY
Click here to add this to my saved trials
Minneapolis, Minnesota 55407
Phone: 612-863-3900
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New York, New York 10016
Phone: 212-263-7149
?
mi
from
New York, NY
Click here to add this to my saved trials
Norfolk, Virginia 23507
Phone: 757-388-2425
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Phone: 407-303-7556
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Phone: 267-584-4422
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
7901 Frost Street
San Diego, California 92123
858-939-3400
Phone: 858-244-6886
Sharp Memorial Hospital Sharp Memorial Hospital offers clinical excellence with the latest technology and patient-centered...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Springfield, Illinois 62701
Phone: 217-492-9100
?
mi
from
Springfield, IL
Click here to add this to my saved trials